<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Intensity of continuous renal replacement therapy for acute kidney injury - Fayad, AI - 2016 | Cochrane Library</title> <meta content="Intensity of continuous renal replacement therapy for acute kidney injury - Fayad, AI - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010613.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Intensity of continuous renal replacement therapy for acute kidney injury - Fayad, AI - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010613.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010613.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Intensity of continuous renal replacement therapy for acute kidney injury" name="citation_title"/> <meta content="Alicia I Fayad" name="citation_author"/> <meta content="Ricardo Gutierrez Children's Hospital" name="citation_author_institution"/> <meta content="aliciafayad@gmail.com" name="citation_author_email"/> <meta content="Daniel G Buamscha" name="citation_author"/> <meta content="Juan Garrahan Children's Hospital" name="citation_author_institution"/> <meta content="Agustín Ciapponi" name="citation_author"/> <meta content="Institute for Clinical Effectiveness and Health Policy (IECS‐CONICET)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD010613.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/10/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010613.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010613.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010613.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Kidney Injury [mortality, *therapy]; Hypophosphatemia [etiology]; Length of Stay; Randomized Controlled Trials as Topic; Recovery of Function; Renal Dialysis [methods]; Renal Replacement Therapy [adverse effects, *methods]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010613.pub2&amp;doi=10.1002/14651858.CD010613.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6iOnQIUh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010613\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010613\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010613.pub2",title:"Intensity of continuous renal replacement therapy for acute kidney injury",firstPublishedDate:"Oct 4, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010613.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010613.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010613.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010613.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010613.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010613.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010613.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010613.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010613.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010613.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3867 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010613.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-sec-0082"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-sec-0076"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/appendices#CD010613-sec-0087"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/table_n/CD010613StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/table_n/CD010613StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Intensity of continuous renal replacement therapy for acute kidney injury</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/information#CD010613-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Alicia I Fayad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/information#CD010613-cr-0003">Daniel G Buamscha</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010613.pub2/information#CD010613-cr-0004">Agustín Ciapponi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/information/en#CD010613-sec-0091">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 October 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010613.pub2">https://doi.org/10.1002/14651858.CD010613.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010613-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010613-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010613-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010613-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010613-abs-0001" lang="en"> <section id="CD010613-sec-0001"> <h3 class="title" id="CD010613-sec-0001">Background</h3> <p>Acute kidney injury (AKI) is a common condition among patients in intensive care units (ICU), and is associated with substantial morbidity and mortality. Continuous renal replacement therapy (CRRT) is a blood purification technique used to treat the most severe forms of AKI but its effectiveness remains unclear. </p> </section> <section id="CD010613-sec-0002"> <h3 class="title" id="CD010613-sec-0002">Objectives</h3> <p>To assess the effects of different intensities (intensive and less intensive) of CRRT on mortality and recovery of kidney function in critically ill AKI patients. </p> </section> <section id="CD010613-sec-0003"> <h3 class="title" id="CD010613-sec-0003">Search methods</h3> <p>We searched Cochrane Kidney and Transplant's Specialised Register to 9 February 2016 through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE, and EMBASE; handsearching conference proceedings; and searching the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. We also searched LILACS to 9 February 2016. </p> </section> <section id="CD010613-sec-0004"> <h3 class="title" id="CD010613-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs). We included all patients with AKI in ICU regardless of age, comparing intensive (usually a prescribed dose <b>≥</b>35 mL/kg/h) versus less intensive CRRT (usually a prescribed dose &lt; 35 mL/kg/h). For safety and cost outcomes we planned to include cohort studies and non‐RCTs. </p> </section> <section id="CD010613-sec-0005"> <h3 class="title" id="CD010613-sec-0005">Data collection and analysis</h3> <p>Data were extracted independently by two authors. The random‐effects model was used and results were reported as risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes, with 95% confidence intervals (CI). </p> </section> <section id="CD010613-sec-0006"> <h3 class="title" id="CD010613-sec-0006">Main results</h3> <p>We included six studies enrolling 3185 participants. Studies were assessed as being at low or unclear risk of bias. There was no significant difference between intensive versus less intensive CRRT on mortality risk at day 30 (5 studies, 2402 participants: RR 0.88, 95% CI 0.71 to 1.08; I<sup>2</sup> = 75%; <i>low quality of evidence</i>) or after 30 days post randomisation (5 studies, 2759 participants: RR 0.92, 95% CI 0.80 to 1.06; I<sup>2</sup> = 65%; <i>low quality of evidence</i>). There were no significant differences between intensive versus less intensive CRRT in the numbers of patients who were free of RRT after CRRT discontinuation (5 studies, 2402 participants: RR 1.12, 95% CI 0.91 to 1.37; I<sup>2</sup> = 71%; <i>low quality of evidence</i>) or among survivors at day 30 (5 studies, 1415 participants: RR 1.03, 95% CI 0.96 to 1.11; I<sup>2</sup> = 69%; <i>low quality of evidence</i>) and day 90 (3 studies, 988 participants: RR 0.98, IC 95% 0.94 to 1.01, I<sup>2</sup> = 0%; moderate<i>quality of evidence</i>). There were no significant differences between intensive and less intensive CRRT on the number of days in hospital (2 studies, 1665 participants): MD ‐0.23 days, 95% CI ‐3.35 to 2.89; I<sup>2</sup> = 8%; <i>low quality of evidence</i>) and the number of days in ICU (2 studies, 1665 participants: MD ‐0.58 days, 95% CI ‐3.73 to 2.56, I<sup>2</sup> = 19%; <i>low quality of evidence</i> ). Intensive CRRT increased the risk of hypophosphataemia (1 study, 1441 participants: RR 1.21, 95% CI 1.11 to 1.31; <i>high quality evidence</i>) compared to less intensive CRRT. There was no significant differences between intensive and less intensive CRRT on numbers of patients who experienced adverse events (3 studies, 1753 participants: RR 1.08, 95% CI 0.73 to 1.61; I<sup>2</sup> = 16%; <i>moderate quality of evidence</i>). In the subgroups analysis by severity of illness and by aetiology of AKI, intensive CRRT would seem to reduce the risk mortality (2 studies, 531 participants: RR 0.73, 95% CI 0.61 to 0.88; I<sup>2</sup> = 0%; <i>high quality of evidence</i>) only in the subgroup of patients with post‐surgical AKI. </p> </section> <section id="CD010613-sec-0007"> <h3 class="title" id="CD010613-sec-0007">Authors' conclusions</h3> <p>Based on the current low quality of evidence identified, more intensive CRRT did not demonstrate beneficial effects on mortality or recovery of kidney function in critically ill patients with AKI. There was an increased risk of hypophosphataemia with more intense CRRT. Intensive CRRT reduced the risk of mortality in patients with post‐surgical AKI. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010613-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010613-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010613-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010613-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010613-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010613-abs-0003" lang="en"> <h3>Intensity of continuous renal replacement therapy for acute kidney injury</h3> <p><b>What is the issue?</b> </p> <p>Acute kidney injury (AKI) is very common among patients admitted to intensive care units (ICU), it is associated with a high death rated and characterised by the rapid loss of the kidney function. Patients with AKI show increased levels of serum uraemic toxins (creatinine and urea), serum potassium and metabolic acids, accumulation of water and in the most cases a reduction in urine output. In this population these chemicals and fluid overload are related to increased rates of death. Theoretically, effective removal of toxins and excess water from the bloodstream might improve patient outcomes (such as mortality rate and recovery of kidney function). </p> <p>Continuous renal replacement therapy (CRRT) is a blood purification technique that enables removal of excess water and toxins. CRRT involves blood being diverted from the patient via a catheter (a hollow, flexible tube placed into a vein) through a filtering system which continuously and steadily removes excess water and toxins; purified blood is then returned to the patient via the catheter. Higher intensity CRRT improves the removal of toxins and excess water. The aim of this review was to investigate the effect of different intensities of CRRT (intensive or less intensive) on death, recovery of kidney function, and adverse events in people with AKI who are critically ill. </p> <p><b>What did we do?</b> </p> <p>We searched the literature up until February 2016 and identified six studies enrolling 3185 patients with AKI that were evaluated in this review. </p> <p><b>What did we find?</b> </p> <p>Six randomised studies enrolling 3185 participants were included in our review. Compared to less intensive CRRT, intensive CRRT did not reduce the risk of death, improve the recovery of kidney function, or reduce the risk of adverse events (such as bleeding) in patients with AKI. Intensive CRRT was associated with an increased risk of low blood phosphate levels. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010613-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010613-sec-0082"></div> <h3 class="title" id="CD010613-sec-0083">Implications for practice</h3> <section id="CD010613-sec-0083"> <p>With available data of included RCTs, more intensive CRRT (range between 35 to 48 mL/kg/h) demonstrated no beneficial effects on mortality or recovery of kidney function, however there was an increased risk of hypophosphataemia compared to less intensive therapy (range between 20 to 25 mL/kg/h). The absence of high quality evidence of efficacy and the possibility of increased adverse events does not support the routine use of high intensity CRRT in this group of patients. However, in patients with post‐surgical AKI, high intensity CRRT appears to reduce the risk of death. </p> <p>These results do not minimise the importance of the intensity in continuous treatment of critically ill patients with AKI. Minimal standards for the delivered dialysis dose of therapy appear to have been identified (<a href="./references#CD010613-bbs2-0045" title="KDIGO . Dialysis interventions for treatment of AKI. Kidney International ‐ Supplement2012;2:89‐115. [DOI: 10.1038/kisup.2011.35] ">KDIGO 2012</a>). There is evidence to suggest that the mortality in these high‐risk populations will be substantially altered by improvements in the delivery kidney support. </p> <p>Our results are likely to have implications for clinical practice in countries (Europe; New Zealand and Australia) where CRRT is now the preferred form of RRT in the ICU (<a href="./references#CD010613-bbs2-0069" title="UchinoS , KellumJA , BellomoR , DoigGS , MorimatsuH , MorgeraS , et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA2005;294(7):813‐8. [MEDLINE: 16106006] ">Uchino 2005</a>). However, in clinical practice, haemodynamically unstable patients are commonly managed using CRRT and haemodynamically stable patients are generally treated using IHD; frequently these patients receive both modalities over the course of their illness as their haemodynamic status change. </p> </section> <h3 class="title" id="CD010613-sec-0084">Implications for research</h3> <section id="CD010613-sec-0084"> <p>Given the persistently high mortality rate among patients with AKI, it would be important to accurately determine the effect of intensity of CRRT on mortality particularly in patients with postsurgical AKI. In view of the inconsistencies observed in the main outcomes and the inability to assess all possible causes of heterogeneity, it would be important to perform pooled analyses of individual patient data from all completed studies to deal with heterogeneity issues. Such an initiative (a patient‐level meta‐analysis of all of the intensity of RRT studies) is being conducted by the <a href="http://www.georgeinstitute.org.au/units/renal-and-metabolic" target="_blank">George Institute for Global Health</a> in Australia. </p> <p>Optimal timing of CRRT initiation during therapy needs to be rigorously evaluated. It would be important to perform pooled analysis of individual patient data from all completed studies to deal with heterogeneity issues. </p> <p>There is also a need to investigate other strategies that can be implemented alone or concurrently to CRRT for the treatment of AKI. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010613-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010613-sec-0015"></div> <div class="table" id="CD010613-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intensive versus less intensive continuous renal replacement therapy (CRRT) for acute kidney injury (AKI)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intensive versus less intensive CRRT for AKI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with AKI<br/> <b>Settings:</b> ICU<br/> <b>Intervention:</b> Intensive versus less intensive CRRT </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Less intensive CRRT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Intensive CRRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality at day 30</b> <br/> Follow‐up: 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.88</b> <br/> (0.81 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2402 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>430 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>420 per 1000</b> <br/> (412 to 523) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality after 30 days post‐randomisation</b> <br/> Follow‐up: 60 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/> (0.80 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2759 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>514 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>483 per 1000</b> <br/> (416 to 565) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>593 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>557 per 1000</b> <br/> (480 to 652) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Patients free of RRT after discontinuing CRRT</b> <br/> Follow‐up: 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.12</b> <br/> (0.91 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2402 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>483 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>541 per 1000</b> <br/> (439 to 661) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>390 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>437 per 1000</b> <br/> (355 to 534) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Patients free of RRT after discontinuing CRRT</b> <br/> Follow‐up: 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/> (0.94 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>988 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>923 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>904 per 1000</b> <br/> (867 to 932) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>784 per 1000</b> <br/> (752 to 808) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: hypophosphataemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.21</b> <br/> (1.11 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1441 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>540 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>654 per 1000</b> <br/> (600 to 708) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>540 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>653 per 1000</b> <br/> (599 to 707) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval/s; <b>RR:</b> Risk ratio; <b>RRT</b>: renal replacement therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ inconsistency: due to substantial heterogeneity (I<sup>2</sup> values ranged from 73% to 78%) </p> <p>² imprecision: due to wide CI which crossed the threshold for clinically meaningful effects </p> <p>³ Indirectness: critically ill patients with AKI in CRRT have high short‐term mortality risk; mortality is a competing end point for kidney recovery at day 90 </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010613-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intensive versus less intensive continuous renal replacement therapy (CRRT) for acute kidney injury (AKI): subgroups</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intensive versus less intensive CRRT for AKI: subgroups</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with AKI who need CRRT<br/> <b>Settings:</b> ICU<br/> <b>Intervention:</b> Intensive CRRT<br/> <b>Comparison:</b> Less intensive CRRT </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Standard dose</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> High dose </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality: patients with sepsis</b> <br/> Follow‐up: mean 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.94</b> <br/> (0.69 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>966 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>524 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>492 per 1000</b> <br/> (361 to 665) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>618 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>581 per 1000</b> <br/> (426 to 785) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality: patients without sepsis</b> <br/> Follow‐up: mean 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.89</b> <br/> (0.69 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1216 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>414 per 1000</b> <br/> (321 to 535) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>564 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>502 per 1000</b> <br/> (389 to 649) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality: patients with AKI related to cardiac or general surgery</b> <br/> Follow‐up: mean 21 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.73</b> <br/> (0.61 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>531 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>505 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>368 per 1000</b> <br/> (308 to 444) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>459 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>335 per 1000</b> <br/> (280 to 404) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality: patients with AKI not related to surgery</b> <br/> Follow‐up: mean 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.94</b> <br/> (0.73 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1871 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>414 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b> <br/> (302 to 497) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>550 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>517 per 1000</b> <br/> (402 to 660) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval/s; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ inconsistency: due to substantial heterogeneity (I<sup>2</sup> values ranged from 73% to 78%) </p> <p>² imprecision: due to wide CI which crossed the threshold for clinically meaningful effects </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010613-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010613-sec-0016"></div> <section id="CD010613-sec-0017"> <h3 class="title" id="CD010613-sec-0017">Description of the condition</h3> <p>Acute kidney injury (AKI) is a complex clinical entity characterised by an abrupt decline in kidney function (<a href="./references#CD010613-bbs2-0052" title="MehtaRL , KellumJA , ShahSV , MolitorisBA , RoncoC , WarnockDG , et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Critical Care (London, England)2007;1(2):R31. [MEDLINE: 17331245] ">Mehta 2007</a>). AKI incidence among adults admitted to intensive care units (ICU) range from 5% to 20% (<a href="./references#CD010613-bbs2-0042" title="HosteEA , ClermontG , KerstenA , VenkataramanR , AngusDC , DeBacquerD , et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Critical Care (London, England)2006;10(3):R73. [MEDLINE: 16696865] ">Hoste 2006</a>; <a href="./references#CD010613-bbs2-0043" title="JoannidisM , MetnitzPG . Epidemiology and natural history of acute renal failure in the ICU. Critical Care Clinics2005;21(2):239–49. [MEDLINE: 15781160] ">Joannidis 2005</a>); in children the incidence is 10% (<a href="./references#CD010613-bbs2-0063" title="SchneiderJ , KhemaniR , GrushkinC , BartR . Serum creatinine as stratified in the RIFLE score for acute kidney injury is associated with mortality and length of stay for children in the pediatric intensive care unit. Critical Care Medicine2010;38(3):933–9. [MEDLINE: 20124891] ">Schneider 2010</a>). Despite its potential to be reversed, AKI is associated with high rates of morbidity and mortality (<a href="./references#CD010613-bbs2-0022" title="BagshawSM , GeorgeC , BellomoR , ANZICS Database Management Committee. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Critical Care (London, England)2007;11(3):R68. [MEDLINE: 17588270] ">Bagshaw 2007</a>). AKI‐related mortality substantially increases among people with multi‐organ failure, sepsis or who are receiving renal replacement therapy (RRT) (<a href="./references#CD010613-bbs2-0053" title="MetnitzPG , KrennCG , SteltzerH , LangT , PloderJ , LenzK , et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Critical Care Medicine2002;30(9):2051–8. [MEDLINE: 12352040] ">Metnitz 2002</a>; <a href="./references#CD010613-bbs2-0067" title="SutherlandSM , ZappitelliM , AlexanderSR , ChuaAN , BrophyPD , BunchmanTE , et al. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. American Journal of Kidney Diseases2010;55(2):316–25. [MEDLINE: 20042260] ">Sutherland 2010</a>). More than 70% of people with AKI need renal support therapies. Despite advances in clinical care, people with AKI are at high risk of mortality and morbidity, and require significant healthcare resources (<a href="./references#CD010613-bbs2-0067" title="SutherlandSM , ZappitelliM , AlexanderSR , ChuaAN , BrophyPD , BunchmanTE , et al. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. American Journal of Kidney Diseases2010;55(2):316–25. [MEDLINE: 20042260] ">Sutherland 2010</a>; <a href="./references#CD010613-bbs2-0069" title="UchinoS , KellumJA , BellomoR , DoigGS , MorimatsuH , MorgeraS , et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA2005;294(7):813‐8. [MEDLINE: 16106006] ">Uchino 2005</a>). </p> </section> <section id="CD010613-sec-0018"> <h3 class="title" id="CD010613-sec-0018">Description of the intervention</h3> <p>Continuous renal replacement therapy (CRRT) is an extracorporeal blood purification therapy, intended to support impaired kidney function. CRRT slowly removes fluid over prolonged periods (<a href="./references#CD010613-bbs2-0034" title="FolandJA , FortenberryJD , WarshawBL , PettignanoR , MerrittRK , HeardML , et al. Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. Critical Care Medicine2004;32(8):1771–6. [MEDLINE: 15286557] ">Foland 2004</a>; <a href="./references#CD010613-bbs2-0035" title="GibneyN , CerdaJ , DavenportA , RamirezJ , SingbartlK , LeblancM , et al. Volume management by renal replacement therapy in acute kidney injury. International Journal of Artificial Organs2008;31(2):145‐55. [MEDLINE: 18311730] ">Gibney 2008</a>; <a href="./references#CD010613-bbs2-0036" title="GoldsteinS , CurrierH , GrafJM , CosioCC , BrewerED , SachdevaR . Outcome in children receiving continuous venovenous hemofiltration. Pediatrics2001;107(6):1309‐12. [MEDLINE: 11389248] ">Goldstein 2001</a>; <a href="./references#CD010613-bbs2-0051" title="MehtaRL , LetteriJM . Current status of renal replacement therapy for acute renal failure. A survey of US nephrologists. The National Kidney Foundation Council on Dialysis. American Journal of Nephrology1999;19(3):377–82. [MEDLINE: 10393374] ">Mehta 1999</a>), removes higher molecular weight solutes efficiently (<a href="./references#CD010613-bbs2-0027" title="BrunnetS , LeblancM , GeadahD , ParentD , CourteauS , CardinalJ . Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. American Journal of Kidney Diseases1999;34(3):486–92. [MEDLINE: 10469859] ">Brunnet 1999</a>; <a href="./references#CD010613-bbs2-0028" title="ClarkWR , RoncoC . CRRT efficiency and efficacy in relation to solute size. Kidney International ‐ Supplement1999;56(72):S3‐7. [MEDLINE: 10560796] ">Clark 1999</a>; <a href="./references#CD010613-bbs2-0047" title="LiaoZ , ZhangW , HardyPA , PohCK , HuangZ , KrausMA , et al. Kinetic comparison of different acute dialysis therapies. Artificial Organs2003;27(9):802–7. [MEDLINE: 12940902] ">Liao 2003</a>; <a href="./references#CD010613-bbs2-0062" title="RoncoC , BrendolanA , LonnemannG , BellomoR , PiccinniP , DigitoA , et al. A pilot study of coupled plasma filtration with adsorption in septic shock. Critical Care Medicine2002;30(6):1250–5. [MEDLINE: 12072677] ">Ronco 2002</a>; <a href="./references#CD010613-bbs2-0066" title="SieberthHG , StummvollHK , KierdoffH (editors) . Continuous extracorporeal treatment in multiple organ dysfunction syndrome: 3rd International Conference on Continuous Hemofiltration. Vienna, July 8, 1994 (Contributions to Nephrology). Vol. 116, Basal: Karger, 1995. ">Sieberth 1995</a>), and confers beneficial haemodynamic stability effects. CRRT modalities are defined by their main solute clearance mechanism. These are convection (continuous venovenous haemofiltration (CVVH)), diffusion (continuous venovenous haemodialysis (CVVHD)), or a combination of both convection and diffusion (continuous venovenous haemodiafiltration, CVVHDF) (<a href="./references#CD010613-bbs2-0057" title="PalevskyPM , BunchmanT , TettaC . The Acute Dialysis Quality Initiative‐‐part V: operational characteristics of CRRT. Advances in Renal Replacement Therapy2002;9(4):268–72. [MEDLINE: 12382230] ">Palevsky 2002</a>). Several interventions have been used over the past three decades with the aim of improving poor prognoses of people with AKI. A significant factor that may impact on CRRT outcomes is intensity of treatment (timing of CRRT for AKI is being investigated in another Cochrane review, <a href="./references#CD010613-bbs2-0033" title="FayadAI , BuamschaDG , CiapponiA . Timing of continuous renal replacement therapy initiation for acute kidney injury. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD010612] ">Fayad 2013a</a>). </p> <p>CRRT intensity is generally related to the quantity of solute removal required to improve outcomes in people with AKI. CRRT intensity can be analysed based either on solute removal from the blood, or appearance of solutes in effluent fluid. Some published studies have used effluent flow rates, expressed as total effluent volume/weight and unit of time (mL/kg/h), as a dose surrogate (<a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>), while accounting for effects of pre‐dilution and modality differences (<a href="./references#CD010613-bbs2-0030" title="Claure‐Del GranadoR , MacedoE , ChertowGM , SorokoS , HimmelfarbJ , IkizlerTA , et al. Effluent volume in continuous renal replacement therapy overestimates the delivered dose of dialysis.[Erratum appears in Clin J Am Soc Nephrol. 2011 Jul;6(7):1802]. Clinical Journal of The American Society of Nephrology: CJASN2011;6(3):467–75. [MEDLINE: 21115626] ">Claure‐Del Granado 2011</a>). Elsewhere, authors have considered that dialysis doses delivered as total effluent volume/clearance of solutes such as urea, creatinine is a better method to measure dose (<a href="./references#CD010613-bbs2-0049" title="LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952–6. [MEDLINE: 21896498] ">Lyndon 2012</a>). Equivalent renal urea clearance also provides a good estimate of delivered dialysis dose in CRRT (<a href="./references#CD010613-bbs2-0031" title="Claure‐Del GranadoR , MacedoE , ChertowGM , SorokoS , HimmelfarbJ , IkizlerTA , et al. Toward the optimal dose metric in continuous renal replacement therapy. International Journal of Artificial Organs2012;35(6):413‐24. [MEDLINE: 22466995] ">Claure‐Del Granado 2012</a>) which can be converted to effluent rate and expressed as mL/kg/h (<a href="./references#CD010613-bbs2-0050" title="MarshallMR . Current status of dosing and quantification of acute renal replacement therapy. Part 2: dosing paradigms and clinical implementation. Nephrology2006;11(3):181‐91. [MEDLINE: 16756629] ">Marshall 2006</a>). </p> <p>Few studies have assessed other dimensions of dose such as electrolyte and acid‐base homeostasis (<a href="./references#CD010613-bbs2-0023" title="BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] ">Bellomo 2013</a>; <a href="./references#CD010613-bbs2-0024" title="BihoracA , RossEA . Continuous venovenous hemofiltration with citrate‐based replacement fluid: efficacy, safety, and impact on nutrition. American Journal of Kidney Diseases2005;46(5):908‐18. [MEDLINE: 16253732] ">Bihorac 2005</a>; <a href="./references#CD010613-bbs2-0054" title="MorimatsuH ,  UchinoS , BellomoR ,  RoncoC . Continuous renal replacement therapy: does technique influence electrolyte and bicarbonate control?. International Journal of Artificial Organs2003;26(4):289‐96. [MEDLINE: 12757027] ">Morimatsu 2003</a>; <a href="./references#CD010613-bbs2-0068" title="UchinoS , BellomoR , RoncoC . Intermittent versus continuous renal replacement therapy in the ICU: impact on electrolyte and acid‐base balance. Intensive Care Medicine2001;27(6):1031‐47. [MEDLINE: 11497136] ">Uchino 2001</a>) and fluid balance/fluid overload (<a href="./references#CD010613-bbs2-0026" title="BouchardJ , SorokoSB , ChertowGM , HimmelfarbJ , IkizlerTA , PaganiniEP , et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney International2009;76(4):422–7. [MEDLINE: 19436332] ">Bouchard 2009</a>; <a href="./references#CD010613-bbs2-0032" title="DavenportA , FarringtonK . Dialysis dose in acute kidney injury and chronic dialysis. Lancet2010;375(9716):705‐6. [MEDLINE: 20167358] ">Davenport 2010</a>; <a href="./references#CD010613-bbs2-0067" title="SutherlandSM , ZappitelliM , AlexanderSR , ChuaAN , BrophyPD , BunchmanTE , et al. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. American Journal of Kidney Diseases2010;55(2):316–25. [MEDLINE: 20042260] ">Sutherland 2010</a>) using effluent volume as the dose measure. </p> </section> <section id="CD010613-sec-0019"> <h3 class="title" id="CD010613-sec-0019">How the intervention might work</h3> <p>A hypothesis that high intensity of RRT may improve survival has emerged from animal and human studies. These findings include indirect evidence from patients with ESKD (<a href="./references#CD010613-bbs2-0048" title="LowrieEG , LairdNM , ParkerTF , SargentJA . Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. New England Journal of Medicine1981;305(20):1176–81. [MEDLINE: 7027040] ">Lowrie 1981</a>; <a href="./references#CD010613-bbs2-0060" title="ParkerTF3rd , HusniL , HuangW , LewN , LowrieEG . Survival of hemodialysis patients in the United States is improved with a greater quantity of dialysis. American Journal of Kidney Diseases1994;23(5):670–80. [MEDLINE: 8172209] ">Parker 1994</a>). </p> <p>Intensity based on a urea kinetics model was evaluated in animal studies by <a href="./references#CD010613-bbs2-0038" title="GrootendorstAF , vanBommelEF , van derHovenB , vanLeengoedLA , vanOstaAL . High volume hemofiltration improves right ventricular function in endotoxin‐induced shock in the pig. Intensive Care Medicine1992;18(4):235‐40. [MEDLINE: 1430589] ">Grootendorst 1992</a>, and in severe ill patients (sepsis, sepsis‐shock) who received high dose (60 to 80 mL/kg/h) reported improvement in haemodynamic state with possible benefits in clinical outcomes (<a href="./references#CD010613-bbs2-0041" title="HonorePM , JamezJ , WauthierM , LeePA , DugernierT , PirenneB , et al. Prospective evaluation of short‐term, high‐volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Critical Care Medicine2000;28(11):3581–7. [MEDLINE: 11098957] ">Honore 2000</a>). A retrospective study found that dose correlated with survival in patients with intermediate scores of illness (<a href="./references#CD010613-bbs2-0056" title="PaganiniEP , SandyD , MorenoL , KozlowskiL , SakaiK . The effect of sodium and ultrafiltration modelling on plasma volume changes and haemodynamic stability in intensive care patients receiving haemodialysis for acute renal failure: a prospective, stratified, randomized, cross‐over study. Nephrology Dialysis Transplantation1996;11 Suppl 8:32‐7. [MEDLINE: 9044338] ">Paganini 1996</a>). Although prospective dose studies demonstrated association of improved survival or kidney recovery with high dose dialysis (<a href="./references#CD010613-bbs2-0061" title="PhuNH , HienTT , MaiNT , ChauTT , ChuongLV , LocPP , et al. Hemofiltration and peritoneal dialysis in infection‐associated acute renal failure in Vietnam. New England Journal of Medicine2002;347(12):895–902. [MEDLINE: 12239258] ">Phu 2002</a>; <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>), these advantages were not universally observed (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>; <a href="./references#CD010613-bbs2-0055" title="NegashDT , DhingraVK , CoplandM , GriesdaleD , HendersonW . Intensity of continuous renal replacement therapy in acute kidney injury in the intensive care unit: a systematic review and meta‐analysis. Vascular &amp; Endovascular Surgery2011;45(6):504‐10. [MEDLINE: 21646231] ">Negash 2011</a>; <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0018" title="VesconiS , CruzDN , FumagalliR , Kindgen‐MillesD , MontiG , MarinhoA , et al. Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Critical Care (London, England)2009;13(2):1‐14. [MEDLINE: 19368724] ">Vesconi 2009</a>; <a href="./references#CD010613-bbs2-0070" title="VanWertR , FriedrichJO , ScalesDC , WaldR , AdhikariNK , University of Toronto Acute Kidney Injury Research Group. High‐dose renal replacement therapy for acute kidney injury: systematic review and meta‐analysis. Critical Care Medicine2010;38(5):1360‐9. [MEDLINE: 20308884] ">Van Wert 2010</a>). </p> <p>Few studies have researched other components of dose that play important roles in clinical results. These include fluid balance and fluid overload associated with increased mortality risk (<a href="./references#CD010613-bbs2-0026" title="BouchardJ , SorokoSB , ChertowGM , HimmelfarbJ , IkizlerTA , PaganiniEP , et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney International2009;76(4):422–7. [MEDLINE: 19436332] ">Bouchard 2009</a>; <a href="./references#CD010613-bbs2-0036" title="GoldsteinS , CurrierH , GrafJM , CosioCC , BrewerED , SachdevaR . Outcome in children receiving continuous venovenous hemofiltration. Pediatrics2001;107(6):1309‐12. [MEDLINE: 11389248] ">Goldstein 2001</a>), adequate homeostasis of electrolytes (sodium, potassium and hydrogen ions) related to cardiovascular stability, and the maintenance of kidney blood flow (<a href="./references#CD010613-bbs2-0068" title="UchinoS , BellomoR , RoncoC . Intermittent versus continuous renal replacement therapy in the ICU: impact on electrolyte and acid‐base balance. Intensive Care Medicine2001;27(6):1031‐47. [MEDLINE: 11497136] ">Uchino 2001</a>). </p> </section> <section id="CD010613-sec-0020"> <h3 class="title" id="CD010613-sec-0020">Why it is important to do this review</h3> <p>Studies assessing CRRT intensity (intensive versus less intensive) have either not reported investigation of all variables inherent in therapy for people with AKI or report inconsistent results. We investigated the relationship between different intensities of CRRT and clinical outcomes for people with AKI. Review evidence could have direct relevance to decisions about optimal intensity of CRRT to improve survival in critically ill patients with AKI. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010613-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010613-sec-0021"></div> <p>To assess the effects of different intensities (intensive and less intensive) of CRRT on mortality and recovery of kidney function in critically ill AKI patients. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010613-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010613-sec-0022"></div> <section id="CD010613-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010613-sec-0024"> <h4 class="title">Types of studies</h4> <p>All RCTs and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at CRRT modalities for people with AKI in ICU settings were eligible for inclusion. For outcomes such us safety and costs, non‐RCTs and cohort studies were also to be included if sufficiently high quality, sampling was clearly described, patients characterised, proportions of patients experiencing any adverse events or who dropped out because of adverse events was adequately reported, co‐interventions were described, and at least 80% of patients included were analysed after treatment. </p> </section> <section id="CD010613-sec-0025"> <h4 class="title">Types of participants</h4> <section id="CD010613-sec-0026"> <h5 class="title">Inclusion criteria</h5> <p>We included all patients with AKI in ICU being treated with CRRT regardless of age or gender. We assigned AKI definitions cited by the included studies. </p> </section> <section id="CD010613-sec-0027"> <h5 class="title">Exclusion criteria</h5> <p>We excluded patients who received dialysis treatment before admission to ICU, patients admitted for drug overdose (doses exceeding therapeutic requirements), or with acute poisoning (all toxins). </p> </section> </section> <section id="CD010613-sec-0028"> <h4 class="title">Types of interventions</h4> <p>We compared intensive (usually a prescribed dose ≥ 35 mL/kg/h) versus less intensive CRRT (usually a prescribed dose &lt; 35 mL/kg/h). These categories of intensities were defined as published in the original publications. We included all CRRT modalities (CVVH, CVVHD and CVVHDF). </p> </section> <section id="CD010613-sec-0029"> <h4 class="title">Types of outcome measures</h4> <section id="CD010613-sec-0030"> <h5 class="title">Primary outcomes</h5> <section id="CD010613-sec-0031"> <h6 class="title">Death</h6> <p> <ul id="CD010613-list-0001"> <li> <p>Death from any cause at days 7, 15, 30, 60, and 90</p> </li> <li> <p>Death or non‐recovery at 90 days.</p> </li> </ul> </p> </section> <section id="CD010613-sec-0032"> <h6 class="title">Recovery of kidney function</h6> <p> <ul id="CD010613-list-0002"> <li> <p>Numbers of patients free of RRT after discontinuing CRRT</p> </li> <li> <p>Numbers of patients free of RRT after discontinuing CRRT at days 30, 60, and 90.</p> </li> </ul> </p> </section> </section> <section id="CD010613-sec-0033"> <h5 class="title">Secondary outcomes</h5> <section id="CD010613-sec-0034"> <h6 class="title">Metabolic balance</h6> <p> <ul id="CD010613-list-0003"> <li> <p>Numbers of patients who normalised serum electrolytes (potassium, sodium) concentration during CRRT </p> </li> <li> <p>Numbers of patients who normalised serum bicarbonate and base‐excess concentration during CRRT </p> </li> <li> <p>Numbers of patients who normalised serum urea and creatinine concentration during CRRT. </p> </li> </ul> </p> </section> <section id="CD010613-sec-0035"> <h6 class="title">Fluid balance</h6> <p> <ul id="CD010613-list-0004"> <li> <p>Numbers of patients who achieved adequate fluid balance during CRRT.</p> </li> </ul> </p> </section> <section id="CD010613-sec-0036"> <h6 class="title">Adverse events</h6> <p> <ul id="CD010613-list-0005"> <li> <p>Numbers of patients who dropped out because of adverse events (technique or patient‐dependent factors) </p> </li> <li> <p>Numbers of patients experiencing any adverse events</p> </li> <li> <p>Numbers of patients with intervention‐related complications (e.g. disequilibrium, hypokalaemia, hypophosphataemia, hypocalcaemia, bleeding, hypotension) </p> </li> <li> <p>Numbers of patients with catheter‐related complications (early and late).</p> </li> </ul> </p> <p>We looked for differences in overall dropout rates and any adverse effects by type (mild or severe). We defined adverse events severity where medical therapeutic interventions were implied in reporting. Withdrawals due to protocol violation or loss to follow‐up were not included in counts of adverse events. </p> </section> <section id="CD010613-sec-0037"> <h6 class="title">Length of stay</h6> <p> <ul id="CD010613-list-0006"> <li> <p>Days in hospital</p> </li> <li> <p>Days in ICU.</p> </li> </ul> </p> </section> <section id="CD010613-sec-0038"> <h6 class="title">Cost</h6> <p>We planned to assess costs of CRRT modalities including:</p> <p> <ul id="CD010613-list-0007"> <li> <p>Type and number of dialyser filters</p> </li> <li> <p>Use/no use of anticoagulation</p> </li> <li> <p>Types of anticoagulation and anticoagulants</p> </li> <li> <p>Use of replacement fluid</p> </li> <li> <p>Numbers of days on CRRT.</p> </li> </ul> </p> <p>All costs were to be reported in international monetary units.</p> <p> <ul id="CD010613-list-0008"> <li> <p>Cost per day of CRRT (expressed in international monetary units)</p> </li> <li> <p>Length of hospital stay with CRRT</p> </li> <li> <p>Length of ICU stay with CRRT.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD010613-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010613-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Specialised Register</a> to 9 February 2016 through contact with the Information Specialist using search terms relevant to this review. The Specialised Register contains studies identified from the following sources. </p> <p> <ol id="CD010613-list-0009"> <li> <p>Quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register were identified through search strategies for CENTRAL, MEDLINE and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of these strategies as well as a list of handsearched journals, conference, proceedings and currents awareness alert, available in the Specialised Register section of information about <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Kidney and Transplant</a>. </p> <p>See <a href="./appendices#CD010613-sec-0088">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD010613-sec-0041"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD010613-list-0010"> <li> <p>LILACS (Latin American and Caribbean Health Sciences) (from March 1980 to February 2016) </p> </li> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD010613-sec-0042"> <h3 class="title" id="CD010613-sec-0042">Data collection and analysis</h3> <section id="CD010613-sec-0043"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies with potential relevance to the review. Titles and abstracts were screened independently by two authors who discarded studies that were not applicable; however studies and reviews that could include relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts, and if necessary, the full text of these studies to determine which satisfied the inclusion criteria. </p> </section> <section id="CD010613-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions these data were used. We resolved any discrepancy by discussion. </p> </section> <section id="CD010613-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed using the risk of bias assessment tool (<a href="./references#CD010613-bbs2-0040" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (see <a href="./appendices#CD010613-sec-0089">Appendix 2</a>). </p> <p> <ul id="CD010613-list-0011"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD010613-list-0012"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD010613-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>For normally distributed outcomes, we calculated summary estimates of treatment effects using the inverse variance method. For dichotomous outcomes (mortality, kidney recovery and adverse events) results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (length of stay, cost) the mean difference (MD) was used or the standardised mean difference (SMD) if different scales were used. </p> </section> <section id="CD010613-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>Any further information required from the original author was requested by written correspondence (e.g. emailing corresponding author) and any relevant information obtained in this manner was included in the review. Evaluation of important numerical data such as screened, randomised patients as well as intention‐to‐treat, as‐treated and per‐protocol population was carefully performed. Attrition rates, for example drop‐outs, losses to follow‐up and withdrawals were investigated. Issues of missing data and imputation methods (e.g., last‐observation‐carried‐forward) were critically appraised (<a href="./references#CD010613-bbs2-0040" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010613-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi<sup>2</sup> test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I<sup>2</sup> test (<a href="./references#CD010613-bbs2-0039" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I<sup>2</sup> values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD010613-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>If possible, funnel plots were to be used to assess the potential existence of small study bias (<a href="./references#CD010613-bbs2-0040" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010613-sec-0050"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model but the fixed‐effect model was also used to ensure robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD010613-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis was used to explore possible sources of heterogeneity (such as intervention, participant and study quality). Heterogeneity among participants could relate to age, gender, fluid overload (&lt; 10% and &gt; 10% body weight relative to baseline), Intensive CRRT for AKI in homogenous subpopulations such as cardiac surgery or sepsis patients, effects of intensive continuous therapy on severity of illness ‐ high, intermediate and low. We used appropriate scores of illness severity, such as Pediatric Risk of Mortality (PRISM), Pediatric Index of Mortality (PIM), Acute Physiology and Chronic Health Evaluation (Apache), Sequential Organ Failure Assessment (SOFA), and Cleveland Clinic ICU Acute Renal Failure (CCF). </p> </section> <section id="CD010613-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses to explore the influence of the following factors on effect size. </p> <p> <ul id="CD010613-list-0013"> <li> <p>Repeating the analysis excluding unpublished studies</p> </li> <li> <p>Repeating the analysis taking account of risk of bias</p> </li> <li> <p>Repeating the analysis excluding any very long or large studies to establish how much they dominate the results </p> </li> <li> <p>Repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), and country. </p> </li> </ul> </p> <section id="CD010613-sec-0053"> <h5 class="title">'Summary of findings' tables</h5> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD010613-bbs2-0064" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD010613-bbs2-0037" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐study risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD010613-bbs2-0065" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). Two summary of findings tables were created. <a href="./full#CD010613-tbl-0001">summary of findings Table for the main comparison</a> summarizes the main findings for the comparison "Intensive versus less intensive RRT for acute kidney injury". We presented the following outcomes. </p> <p> <ul id="CD010613-list-0014"> <li> <p>Mortality until day 30 post‐randomisation</p> </li> <li> <p>Mortality after 30 days post‐randomisation</p> </li> <li> <p>Kidney function recovery: number of patients free of RRT after discontinuing CRRT</p> </li> <li> <p>Kidney function recovery: number of patients free of RRT after discontinuing CRRT until day 90, among survivals </p> </li> <li> <p>Adverse events: number of patients with hypophosphataemia</p> </li> </ul> </p> <p><a href="./full#CD010613-tbl-0002">summary of findings Table 2</a> summarizes the main mortality findings for the subgroups of patients with AKI with and without sepsis, and related or not to surgery. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010613-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010613-sec-0054"></div> <section id="CD010613-sec-0055"> <h3 class="title">Description of studies</h3> <p>See. <a href="./references#CD010613-sec-0097" title="">Characteristics of included studies</a>; <a href="./references#CD010613-sec-0098" title="">Characteristics of excluded studies</a>; Characteristics of ongoing studies. </p> <section id="CD010613-sec-0056"> <h4 class="title">Results of the search</h4> <p>We identified 185 records from electronic databases (MEDLINE, EMBASE, CENTRAL, Cochrane Kidney and Transplant's Specialised Register, LILACS) to 9 February 2016. We screened these titles and abstracts excluded 117 records. We assessed the full text of 68 potentially eligible records (21 studies). Six studies (52 records) were included in our review (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>; <a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a>; <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>; <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>). One study has recently been completed but no results have been published (<a href="./references#CD010613-bbs2-0021" title="ShiW . Effect of the intensity of continuous renal replacement therapy in patients with acute kidney injury: single‐centre randomised clinical trial. www.clinicaltrials.gov/ct2/show/NCT01560650 (accessed 25 August 2016). ">NCT01560650</a>). Fourteen studies (15 records) were excluded (<a href="#CD010613-fig-0001">Figure 1</a>). There was no disagreement among authors regarding inclusion of studies. </p> <div class="figure" id="CD010613-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD010613-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD010613-sec-0057"> <h4 class="title">Included studies</h4> <p>Six included studies (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>; <a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a>; <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>; <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>) enrolled a total of 3185 participants. </p> <p>Study participants were all admitted to ICU. The mean age ranged from 51 and 68 years, and the proportion of male ranged from 55% to 71%. Sepsis was the primary cause of AKI in four studies (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>; <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>; <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>) and surgery or cardio‐surgery the main cause in the other two (<a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a>; <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>) </p> <p>All studies were reported between 2000 and 2008. Three were single‐centre studies (<a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>; <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>) and three were multicentre (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>; <a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a>; <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>). </p> <p>Four studies used one CRRT modality exclusively; <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a> and <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a> used CVVHDF, and <a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a> and <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a> used CVVH. <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a> used CVVH and CVVHDF and <a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a> used intermittent haemodialysis (IHD) and CVVHDF or sustained low‐efficiency haemodialysis (SLED), depending on the haemodynamic stability of the participant. Replacement fluid was administered either pre filter (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>; <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>) or post filter (<a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a>; <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>; <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>) when either CVVH or CVVHDF were used. </p> <p>Five studies assessed the effects of two intensities of continuous therapy (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>; <a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a>; <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>; <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>), whereas one assessed the effects of three CRRT intensities (standard, intermediate and high) (<a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>). For the purpose of the analysis, we combined the intermediate with high‐dose arm of this study to create one high intensity arm. In <a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a>, two arms received the same less intensive CRRT dose but differed only in the timing of CRRT initiation. We combined these two treatment arms to create one less intensive arm. <a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a> randomly assigned critically ill patients with AKI to high‐intensity or low‐intensity RRT. Within treatment groups, patients were allocated to intermittent (IHD) or prolonged (SLED) and continuous RRT according to cardiovascular SOFA score. Continuous RRT was provided to 69.7% of patients as their initial therapy. However, unstable patients assigned to CRRT had a variable number of switches in treatment modality: none (≈36.1%) or 1 (≈24%) and ≥ 2 modalities (≈10%) (<a href="./references#CD010613-bbs2-0059" title="PalevskyPM , O´ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the acute Renal Failure Trial Network Study. Critical Care (London, England)2009;13(4):310. [MEDLINE: 19678919] ">Palevsky 2009</a>). For the purpose of the analysis, we included all patients initially allocated to continuous CRRT independently of the switches in treatment modality (intention‐to‐treat analysis), who survived to day 60. </p> <p>Five studies prescribed dose according to patients’ weight at the time of admission (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>; <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>; <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>), and only one prescribed dose per unit of time (<a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a>). </p> <p>Overall, the prescribed dose of CRRT in the less intensive arm of included studies ranged between 20 to 25 mL/kg/h and in intensive arm ranged between 35 to 48 mL/kg/h. </p> <p>For full details see <a href="./references#CD010613-sec-0097" title="">Characteristics of included studies</a>. </p> </section> <section id="CD010613-sec-0058"> <h4 class="title">Excluded studies</h4> <p>Fourteen studies were excluded. <a href="./references#CD010613-bbs2-0009" title="ColeL , BellomoR , HartG , JournoisD , DavenportP , TippingP , et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Critical Care Medicine2002;30(1):100‐6. [MEDLINE: 11902250] ">Cole 2002</a> and <a href="./references#CD010613-bbs2-0018" title="VesconiS , CruzDN , FumagalliR , Kindgen‐MillesD , MontiG , MarinhoA , et al. Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Critical Care (London, England)2009;13(2):1‐14. [MEDLINE: 19368724] ">Vesconi 2009</a> compared continuous dialysis therapy versus no haemofiltration or other RRT (intermittent haemodialysis). <a href="./references#CD010613-bbs2-0007" title="BoussekeyN , ChicheA , FaureK , DevosP , GueryB , d'EscrivanT , et al. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Medicine2008;34(9):1646‐53. [MEDLINE: 18542921] ">Boussekey 2008</a>, <a href="./references#CD010613-bbs2-0012" title="Joannes‐BoyauO , HonorePM , PerezP , BagshawSM , GrandH , CanivetJL , et al. High‐volume versus standard‐volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Medicine2013;39(9):1535‐46. [MEDLINE: 23740278] ">IVOIRE Study 2013</a>, <a href="./references#CD010613-bbs2-0017" title="SanchezC , CorbalanP , RodriguezF , SanchezA , PalominosS . Intensive high volume hemofiltration vs very high volume hemofiltration: effects on hemodynamics in patients with severe sepsis: a nursing approach [abstract no: 0432]. Intensive Care Medicine2010;36(2 Suppl 2):S193. ">Sanchez 2010b</a> and <a href="./references#CD010613-bbs2-0020" title="ZhangP , YangY , LvR , ZhangY , XieW , ChenJ . Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a single‐centre randomized clinical trial. Nephrology Dialysis Transplantation2012;27(3):967‐73. [MEDLINE: 21891773] ">Zhang 2012</a> and two ongoing studies (<a href="./references#CD010613-bbs2-0014" title="KimDK , YooTH . Effects of high volume continuous renal replacement therapy in patients with septic acute kidney injury. www.clinicaltrials.gov/ct2/show/NCT01191905 (accessed 25 August 2016). ">NCT01191905</a>; <a href="./references#CD010613-bbs2-0015" title="ChenJ . Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: single‐center randomized clinical trial. www.clinicaltrials.gov/ct2/show/NCT01251081 (accessed 25 August 2016). ">NCT01251081</a>) compared different intensity‐arms treatment. <a href="./references#CD010613-bbs2-0010" title="GhaniRA , ZainudinS , CtkongN , RahmanAF , WafaSR , MohamadM , et al. Serum IL‐6 and IL‐1‐ra with sequential organ failure assessment scores in septic patients receiving high‐volume haemofiltration and continuous venovenous haemofiltration. Nephrology2006;11(5):386‐93. [MEDLINE: 17014550] ZainudinS , GhaniRA , MohdM , WafaSR , TongNK . Stability of haemodynamic parameters during CRRT: a comparison between standard continuous venovenous haemofiltration and high‐volume haemofiltration in patients with acute renal failure and sepsis [abstract no: SP286]. Nephrology Dialysis Transplantation2006;21(Suppl 4):iv108. [CENTRAL: CN‐00583762] ">Ghani 2006</a> and <a href="./references#CD010613-bbs2-0016" title="PayenD , MateoJ , CavaillonJM , FraisseF , FloriotC , VicautE , et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Critical Care Medicine2009;37(3):803‐10. [MEDLINE: 19237881] ">Payen 2009</a> did not provide relevant outcomes for this review. Two studies were not RCTs (<a href="./references#CD010613-bbs2-0008" title="BrauseM , NeumannA , SchumacherT , GrabenseeB , HeeringP . Effect of filtration volume of continuous venovenous hemofiltration in the treatment of patients with acute renal failure in intensive care units. Critical Care Medicine2003;31(3):841‐6. [MEDLINE: 12626994] ">Brause 2003</a>; <a href="./references#CD010613-bbs2-0019" title="ZhaY , YangX , LinX , YuanJ , HuY , LongYJ , et al. Clinical observation of different doses of continuous renal replacement therapy for severe pneumonia with acute kidney injury. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal]2012;92(48):3385‐8. [MEDLINE: 23327695] ">Zha 2012</a>). In <a href="./references#CD010613-bbs2-0011" title="CombesA , BrechotN , AmourJ , CozicN , LebretonG , GuidonC , et al. Early High‐Volume Hemofiltration versus Standard Care for Post‐Cardiac Surgery Shock. The HEROICS Study. American Journal of Respiratory &amp; Critical Care Medicine2015;192(10):1179‐90. [MEDLINE: 26167637] ">HEROICS Study 2015</a>, 36% of control‐arm patients did not receive CRRT. <a href="./references#CD010613-bbs2-0013" title="JiangHL , XueWJ , LiDQ , YinAP , XinX , LiCH , et al. Influence of continuous veno‐venous hemofiltration on the course of acute pancreatitis. World Journal of Gastroenterology2005;11(31):4815‐21. [MEDLINE: 16097050] ">Jiang 2005</a> had different inclusion criteria in relation to our review. Only six patients (16%) with severe pancreatitis have AKI and were treated with CRRT (<a href="./references#CD010613-sec-0098" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD010613-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>Included studies were generally at low or unclear risk of bias for all domains (See <a href="#CD010613-fig-0002">Figure 2</a>; <a href="#CD010613-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD010613-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010613-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD010613-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010613-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD010613-sec-0060"> <h4 class="title">Allocation</h4> <p><a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a> and <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a> did not provide detailed information about random sequence generation and allocation concealment processes. Authors were contacted and we were informed that the random sequence generation was appropriate (computer‐generated) and sealed opaque envelopes were used for the allocation process. All studies were assessed as being at low risk of selection bias due to appropriate random sequence generation and five were allocation concealment processes. The allocation process was considered unclear in <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a> due to disease severity imbalance observed between the study arms. </p> </section> <section id="CD010613-sec-0061"> <h4 class="title">Blinding</h4> <p>All included studies were assessed at low risk of detection bias (outcome measurement was unlikely to be influenced by lack of blinding), and unclear risk of performance bias (insufficient information to enable judgment). </p> </section> <section id="CD010613-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>The risk of attrition bias was low in all included studies. Intention‐to‐treat analysis was performed in all studies. </p> </section> <section id="CD010613-sec-0063"> <h4 class="title">Selective reporting</h4> <p>Published records included all expected outcomes and were considered at low risk of bias. </p> </section> <section id="CD010613-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p>Three studies provided complete information on grant support for authors and studies (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>; <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>). This information was unclear in the remaining three studies. </p> </section> </section> <section id="CD010613-sec-0065"> <h3 class="title" id="CD010613-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD010613-tbl-0001"><b>Summary of findings for the main comparison</b> Intensive versus less intensive continuous renal replacement therapy (CRRT) for acute kidney injury (AKI)</a>; <a href="./full#CD010613-tbl-0002"><b>Summary of findings 2</b> Intensive versus less intensive continuous renal replacement therapy (CRRT) for acute kidney injury (AKI): subgroups</a> </p> <p>The effects of intensive CRRT versus less intensive CRRT for main results and the quality of the evidence are summarised in <a href="./full#CD010613-tbl-0001">summary of findings Table for the main comparison</a> </p> <section id="CD010613-sec-0066"> <h4 class="title">Mortality</h4> <p>All six studies assessed the effect of different intensities of CRRT (intensive versus less intensive treatment) on mortality. These studies varied in mortality reporting timing: at 90 days (<a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>), 60 days (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>), 28 days after randomisation or at ICU discharge (<a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a>; <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>), and 15 days after cessation of CRRT (<a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>). </p> <p>There was no significant difference between intensive versus less intensive CRRT on mortality risk at day 30 (<a href="./references#CD010613-fig-0005" title="">Analysis 1.1</a>.1 (5 studies, 2402 participants): RR 0.88, 95% CI 0.71 to 1.08; I<sup>2</sup> = 75%) or after 30 days post randomisation (<a href="./references#CD010613-fig-0005" title="">Analysis 1.1</a>.2 (5 studies, 2759 participants): RR 0.92, 95% CI 0.80 to 1.06; I<sup>2</sup> = 65%). There was substantial heterogeneity among studies<b>.</b> We downgraded the quality of evidence from high to low due to this inconsistency and imprecision (<a href="./full#CD010613-tbl-0001">summary of findings Table for the main comparison</a>). </p> <section id="CD010613-sec-0067"> <h5 class="title">Subgroup analysis and investigation of heterogeneity</h5> <p>There was evidence of significant heterogeneity in the magnitude of the effect among the included studies that measured mortality at different times of randomisation (at day 30 and after 30 days). To assess heterogeneity among participants we planned to perform the following pre‐specified subgroup analyses: by age, gender, fluid overload (≤ 10% and &gt; 10% in body weight relative to baseline<i>),</i> according to aetiology of AKI and severity of illness. Only data for aetiology of AKI and severity of illness were available. </p> <p>The effect of the severity of illness at baseline was assessed using two subgroups: patients with and without sepsis and patients with high and low SOFA cardiovascular scores (≥ 3 and &lt; 3). The was no significant differences in mortality between intensive versus less intensive CRRT in patients with sepsis (<a href="./references#CD010613-fig-0006" title="">Analysis 1.2</a>.1 (5 studies, 966 participants): RR 0.94; 95% CI 0.69 to 1.27; I<sup>2</sup> = 72%) or without sepsis (<a href="./references#CD010613-fig-0006" title="">Analysis 1.2</a>.2 (4 studies, 1216 participants): RR 0.89, 95% CI 0.69 to 1.15; I<sup>2</sup> = 73%), or in patients with SOFA scores &lt; 3 (<a href="./references#CD010613-fig-0006" title="">Analysis 1.2</a>.3; 1 study, 404 participants: RR 0.91, 95% CI 0.71 to 1.18) or SOFA score <b>≥</b> 3 (<a href="./references#CD010613-fig-0006" title="">Analysis 1.2</a>.4; 1 study, 1056 participants: RR 1.04, 95% CI 0.92 to 1.18). </p> <p>The effect of AKI aetiology was considered using two subgroups: patients with AKI secondary to surgical causes and patients with AKI related to non‐surgical causes. Compared to less intensive CRRT, Intensive CRRT reduced the risk of death in patients with post‐surgical AKI (<a href="./references#CD010613-fig-0006" title="">Analysis 1.2</a>.5 (2 studies, 531 participants): RR 0.73, 95% CI 0.61 to 0.88; I<sup>2</sup> = 0%), but not in patients with AKI related to non‐surgical causes (<a href="./references#CD010613-fig-0006" title="">Analysis 1.2</a>.6 (3 studies, 1871 participants): RR 0.94, 95% CI 0.73 to 1.20; I<sup>2</sup> = 76%). </p> <p>The heterogeneity observed in subgroup analyses could be explained by AKI aetiology (test for subgroup differences: Chi<sup>2</sup> = 9.56; P = 0.09; I<sup>2</sup> = 47.7%). When the post‐surgery AKI group was removed from the analysis, I<sup>2</sup> = 0% (test for subgroup differences: Chi<sup>2</sup> = 1.96, P = 0.74). </p> <p>We downgraded the quality of evidence from high to low due to inconsistency and imprecision on the following subgroup analyses: patients with and without sepsis, patients with high and low SOFA cardiovascular score and patients with non‐surgical AKI. High quality of evidence was found for the subgroup of patients with AKI related to surgery (<a href="./full#CD010613-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD010613-sec-0068"> <h5 class="title">Sensitivity analysis</h5> <p>The sensitivity analysis was performed excluding studies by risk of bias and large studies. When the analysis was developed taking risk of bias into account we observed that <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a> contributed to heterogeneity, and when excluded, heterogeneity was not significant (P = 0.63; I<sup>2</sup> = 0%). The reason for exclusion was significant imbalance in the severity of illness observed between treatment arms. The effect of high intensity on mortality changed, but the direction of effects remained constant. We found no changes in heterogeneity when the study with larger sample size was excluded. </p> <p>Data on death or non‐recovery at 90 days was not available.</p> </section> </section> <section id="CD010613-sec-0069"> <h4 class="title">Recovery of kidney function</h4> <p>Five studies reported information on recovery of kidney function (in all patients and among survivors). Studies varied in reporting of kidney recovery timing: 90 days after randomisation (<a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>); 28 days (<a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>; <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>); at hospital discharge (<a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a>;<a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>); or 15 days after cessation of CRRT (<a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>). </p> <p>Overall, there was no significant difference between intensive versus less intensive CRRT in the numbers of patients who were free of RRT after CRRT discontinuation (<a href="./references#CD010613-fig-0007" title="">Analysis 1.3</a>.1 (5 studies, 2402 participants): RR 1.12, 95% CI 0.91 to 1.37; I<sup>2</sup> = 71%). There was substantial heterogeneity among studies. We downgraded the quality of evidence from high to low due to inconsistence and imprecision. </p> <p>Similarly there was no significant difference between intensive versus less intensive CRRT on recovery of kidney function among survivors who discontinued CRRT at day 30 (<a href="./references#CD010613-fig-0007" title="">Analysis 1.3</a>.2 (5 studies, 1415 participants): RR 1.03, 95% CI 0.96 to 1.11; I<sup>2</sup> = 69%) or at day 90 (<a href="./references#CD010613-fig-0007" title="">Analysis 1.3</a>.3 (3 studies, 988 participants): RR 0.98, IC 95% 0.94 to 1.01, I<sup>2</sup> = 0%). We downgraded the quality of evidence from high to low due to inconsistency and indirectness and rated as moderate quality of evidence, due to indirectness, respectively (<a href="./full#CD010613-tbl-0001">summary of findings Table for the main comparison</a>) </p> <section id="CD010613-sec-0070"> <h5 class="title">Subgroup analysis and investigation of heterogeneity</h5> <p>There was evidence of significant heterogeneity in the magnitude of the effect among the included studies that measured recovery of kidney function at different times in relation to randomisation. To assess heterogeneity among participants, we performed prespecified subgroup analyses by age, gender, fluid overload (≤ 10% and &gt; 10% in body weight in relation to baseline<i>),</i> according to AKI aetiology and severity of illness. Only data for AKI aetiology were available. The effect of AKI aetiology was assessed using subgroups: patients with AKI predominantly related to surgical causes and patients with AKI related to non‐surgical causes. Compared to less intensive CRRT, intensive CRRT increased recovery of kidney function in patients with post‐surgical AKI (<a href="./references#CD010613-fig-0008" title="">Analysis 1.4</a>.1 (2 studies, 531 participants): RR 1.27, 95% CI 1.05 to 1.53, P = 0.01, I<sup>2</sup>= 0%), but there were no difference on recovery of kidney function in patients with AKI related to non‐surgical causes (<a href="./references#CD010613-fig-0008" title="">Analysis 1.4</a>.2 (3 studies, 1870 participants): RR 1.12, 95% CI 0.73 to 1.71, P = 0.61, I<sup>2</sup>= 82%). There was no heterogeneity between groups (test for subgroup differences: Chi<sup>2</sup> = 0.27, P = 0.60, I<sup>2</sup> = 0%). </p> </section> <section id="CD010613-sec-0071"> <h5 class="title">Sensitivity analysis</h5> <p>There was evidence of heterogeneity in recovery of kidney function up to 30 days after discontinuation of CRRT (I<sup>2</sup> = 69%). We performed sensitivity analyses to explore the above listed factors on the effect size. Few data were available. Sensitivity analysis was performed excluding studies with high risk of bias and those with large sample sizes. When the analysis was developed taking risk of bias into account, we observed that <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a> contributed to heterogeneity. When excluded, heterogeneity was not significant (P = 0.63; I<sup>2</sup> = 0%). <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a> included a non‐validated outcome (kidney recovery 15 days after cessation of CRRT) and enrolled patients with high incidence of post‐surgical AKI, which may have contributed to a better prognosis on recovery of kidney function. The effect of intensive CRRT remained constant and the direction of effects did not change. </p> </section> </section> <section id="CD010613-sec-0072"> <h4 class="title">Length of stay</h4> <p><a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a> and <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a> compared the effects of intensity of CRRT on length of stay. There were no significant differences between intensive and less intensive CRRT on the number of days in hospital (<a href="./references#CD010613-fig-0009" title="">Analysis 1.5</a>.1 (2 studies, 1665 participants): MD ‐0.23 days, 95% CI ‐3.35 to 2.89; I<sup>2</sup> = 8%) and the number of days in ICU (<a href="./references#CD010613-fig-0009" title="">Analysis 1.5</a>.2 (2 studies, 1665 participants): MD ‐0.58 days, 95% CI ‐3.73 to 2.56, I<sup>2</sup> = 19%). We downgraded the quality of evidence from high to low due to substantial imprecision and risk of bias. </p> </section> <section id="CD010613-sec-0073"> <h4 class="title">Metabolic control</h4> <p>There was no significant difference between intensive and less intensive CRRT on the numbers of patients who normalised metabolic acidosis (<a href="./references#CD010613-fig-0010" title="">Analysis 1.6</a>.1 (1 study, 115 participants): RR 1.05, 95% CI 0.73 to 1.51). We rated this as moderate quality evidence due to imprecision. </p> </section> <section id="CD010613-sec-0074"> <h4 class="title">Adverse events</h4> <p>The effects of intensity of CRRT on adverse events were reported in three studies (<a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a>; <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>). Intensive CRRT increased the risk of hypophosphataemia (<a href="./references#CD010613-fig-0011" title="">Analysis 1.7</a>.2 (1 study, 1441 participants): RR 1.21, 95% CI 1.11 to 1.31) compared to less intensive CRRT. We rated this as high quality evidence. </p> <p>There were no significant differences between intensive and less intensive CRRT on the numbers of patients who experienced adverse events (<a href="./references#CD010613-fig-0011" title="">Analysis 1.7</a>.1 (3 studies, 1753 participants): RR 1.08, 95% CI 0.73 to 1.61; I<sup>2</sup> = 16%), hypokalaemia (<a href="./references#CD010613-fig-0011" title="">Analysis 1.7</a>.3 (1 study, 1455 participants): RR 0.96, 95% CI 0.80 to 1.15), arrhythmia (<a href="./references#CD010613-fig-0011" title="">Analysis 1.7</a>.4 (1 study, 1463 participants): RR 0.92, 95% CI 0.80 to 1.06), and bleeding (<a href="./references#CD010613-fig-0011" title="">Analysis 1.7</a>.5 (3 studies, 1775 participants): RR 0.78, 95% CI 0.27 to 2.24; I<sup>2</sup> = 0%). We downgraded the quality of evidence from high to moderate due to imprecision and for the last outcome we rate as low quality evidence due to substantial imprecision (<a href="./full#CD010613-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Fluid balance and costs of CRRT were not reported in any of the included studies.</p> </section> <section id="CD010613-sec-0075"> <h4 class="title">Evaluation of publication bias</h4> <p>We constructed a funnel plot to investigate potential publication bias. Meta‐analysis of mortality at day 30 was analysed. We found reasonable symmetry indicating a low risk of publication bias (<a href="#CD010613-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD010613-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 High Intensity versus less intensive CRRT, outcome: 1.1 Mortality" data-id="CD010613-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 High Intensity versus less intensive CRRT, outcome: 1.1 Mortality </p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010613-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010613-sec-0076"></div> <section id="CD010613-sec-0077"> <h3 class="title" id="CD010613-sec-0077">Summary of main results</h3> <p>Our systematic review and subsequent meta‐analysis examines the effect of different intensities of CRRT on mortality, kidney recovery function and adverse events among 3185 critically ill patients with AKI. Most of the included studies were assessed at low or unclear risk of bias for all domains. Within the intensity ranges assessed, more intensive CRRT did not demonstrate beneficial effects on mortality at different time points post randomisation (day 30 or after 30 days) and kidney recovery function (in all patients and among survivals at 30 and 90 days before randomisation) compared with less intensive therapy. The overall estimated effects on these outcomes are not statistically significant; the confidence intervals are sufficiently wide to include clinically benefits and harm (imprecision), with high level of heterogeneity (inconsistency). Treatment with more intensive CRRT increased the risk of hypophosphataemia, although it did not increase other adverse events when compared to less intensive CRRT. All results (except hypophosphataemia) were imprecise because the confidence intervals were wide which crossed the threshold for clinically meaningful effects. </p> <p>An important limitation of this systematic review was the substantial heterogeneity found in the main results as mortality at day 30 or after 30 days (I<sup>2</sup> = 75% and I<sup>2</sup> = 65% respectively) and recovery of kidney function in all patients and among survivals at 30 (I<sup>2</sup> = 71% and I<sup>2</sup> = 69% respectively). However, there was no heterogeneity identified for recovery of kidney function at 90 days (I<sup>2</sup> = 0%). We explored this heterogeneity by two prespecified clinical subgroup analyses; severity of acute illness (patients with and without sepsis and high and low SOFA cardiovascular scores) and by aetiology of AKI. We found that in patients with surgery‐acquired AKI, intensive CRRT reduced mortality risk at day 30 compared to those patients with non‐surgically‐acquired AKI. Therefore, AKI aetiology was identified as a source of heterogeneity in the size of effect among included studies. </p> <p>More intensive CRRT had uncertain effects on length of stay, number of days in ICU and number of days in hospital. These results should be interpreted with caution owing to the fact that only two small studies reported these data. Some studies have reported days in hospital and days in ICU but, in patients with a high short‐term mortality risk, the interpretation of such results may be misleading given the mortality is a competing end point for length of stay. </p> </section> <section id="CD010613-sec-0078"> <h3 class="title" id="CD010613-sec-0078">Overall completeness and applicability of evidence</h3> <p>See <a href="#CD010613-sec-0055">Description of studies</a>; <a href="./references#CD010613-sec-0097" title="">Characteristics of included studies</a> </p> <p>Six randomised studies (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>; <a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002;</a><a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>; <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>) evaluated the effect of different intensities of CRRT on survival and recovery of kidney function in critically ill patients with AKI. Two studies (<a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>) favoured more intensive therapy. In contrast, four other studies (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>; <a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002;</a><a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>) have not demonstrated beneficial effects with an increased intensity of therapy on clinical outcomes. These results are consistent with those reported in our review. </p> <p>Disparity and the heterogeneity found in these results among the studies probably may explained by several factors such as differences in methodological quality of studies, patients characteristics, delivered dialysis dose, and timing of CRRT initiation. </p> <p>In a study of 425 patients, <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a> reported a decrease in mortality at day 15 from 59% to 43% with an increased in the intensity from 20 mL/kg/h to 35 or 45 mL/kg/h. We observed some limitations in this study: an absence of detailed description of randomisation and allocation concealment process (limiting the internal validity); a low incidence of patients with AKI‐related to sepsis (15%); and a non‐validated short‐term outcome (limiting the external validity). In <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a> (206 patients with AKI) there was a 26% reduction in all‐cause of mortality at day 90 (from 62% to 36%) with an increase in the intensity of CRRT from 25 mL/kg/h to 45 mL/kg/h. This study has an important imbalance in the severity of illness observed between CVVH treatment arms (limiting the internal validity). Additionally, both studies were unblinded, single‐centre studies (limiting the internal and external validity respectively). In contrast, three studies evaluating intensity in continuous therapy, and one study in combined modalities (Intermittent and continuous), did not demonstrate any effect of increased intensity of therapy on survival. <a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a> conducted a small study evaluating both intensity and timing of initiation of CVVH in 106 critical patients with AKI. There were no differences on the survival for either intensities or initiation time. It is interesting to note that the actual delivered therapy in the high‐intensity arm was much less than the prescribed intensity. Furthermore, survival was greater than expected (survival at 28 days 69% to 75% in all groups) probably related to a low incidence of patients with AKI‐related to sepsis (limiting the external validity). The study was underpowered due to the small sample size. Similarly, <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a> evaluated 200 patients with AKI. They found no difference on survival with intensive continuous therapy. This was an unblinded, single‐centre study (limiting the internal and external validity respectively). Finally, two large multicentre studies were conducted. In <a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>, 1124 critically ill patients with AKI were randomised to high‐intensity or low‐intensity. Within treatment groups, patients were allocated to CVVHDF or SLED and IHD according to cardiovascular SOFA score. In <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>, 1508 patients were randomly assigned to two intensities of CVVHDF (intensive or less intensive). All patients received CRRT as their first mode of RRT; only a small proportion of patients received IHD (7%). Both studies reported no beneficial effect on mortality and recovery of kidney function associated with a more intensive RRT. </p> <p>There were also differences in the prescribed and delivered doses of CRRT. In <a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>, the dose delivered was 89% of that prescribed for higher‐intensity treatment, <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a> reported a value of 83%, and in <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a> the delivered dose was 84%. For the lower‐intensity treatment, the doses delivered were 95% in <a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>, 85% in <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>, and 88% in <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>. In all other studies (<a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a>; <a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>) delivered doses were less than 85% of the prescribed doses. The difference between the prescribed and the delivered dose highlights the risk of overestimating the effective delivery of therapy and the need to improve operational measures in CRRT. </p> <p>Although the analysis included data obtained from a comprehensive and rigorous search, we identified gaps in several areas. The majority of participants of the included studies were adults, limiting the applicability of our finding to children. In general, the incidence of AKI secondary to sepsis is very high in ICU (50% to 60%); however, in two studies it was observed that the majority of patients had post‐surgical AKI, and relatively few had sepsis or pre‐existing chronic kidney disease, limiting the applicability of our results to general ICU population. Three included studies were single‐centre studies, limiting the external validity of the results. </p> <p>While the urea kinetics remains widely used to measure intensity of RRT in AKI‐patients, this approach provides an incomplete assessment of dose of RRT, especially in the critically ill patients with AKI. </p> <p>An important challenge when examining the evidence of dialysis intensity in patients with AKI is to determine the exact number of patients who received IHD or CRRT in those studies using a combination of both strategies (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>), as well as distinguishing which patients remained dialysis‐depend after ICU discharge or received transitory IHD without regard to the original assigned treatment. In view of this, we contacted the authors for more information. The long‐term kidney outcomes after hospital discharge among survivors of AKI remain poorly characterised. The studies did not report data on mortality and kidney function recovery in patients with pre‐existing chronic kidney disease and with low or intermediate scores of severity of illness. The results on length of stay (days in hospital and in the ICU) and recovery of kidney function should be interpreted with caution, especially when the mortality risk is taken into account. </p> <p>We are aware that an important aspect to consider in term of efficacy is the timing in which CRRT are indicated. Currently, we are trying to answer this question with a systematic review specified (<a href="./references#CD010613-bbs2-0033" title="FayadAI , BuamschaDG , CiapponiA . Timing of continuous renal replacement therapy initiation for acute kidney injury. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD010612] ">Fayad 2013a</a>). </p> <p>We included only RCTs with the purpose of reducing bias.</p> </section> <section id="CD010613-sec-0079"> <h3 class="title" id="CD010613-sec-0079">Quality of the evidence</h3> <p>We conducted this review according to the process described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010613-bbs2-0040" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Our review was based on evidence from six RCTs (3185 participants) that compared different intensities of CRRT in critically ill patients with AKI. The quality of evidence for our main outcomes was drawn from studies assessed at low risk of bias for random sequence generation and allocation concealment processes, incomplete outcome data, intention to treat analysis, selective outcomes reporting, performance bias and other sources of bias; and unclear risk for detection bias. </p> <p>Data comparing the effect of higher intensity versus lower intensity CRRT on mortality at day 30 or after were obtained from six well‐conducted RCTs respectively, but we downgraded the quality of evidence to low, mainly due to inconsistencies (I<sup>2</sup> values of 65% and 75%) and imprecision (CIs included a range of plausible values with clinically important benefits but also included harms). Similarly, we downgraded the quality of evidence to low for recovery of kidney function in all patients and among survivors at day 30 due to inconsistencies (I<sup>2</sup> values of 71% and 69%) and rated as moderate data obtained for recovery of kidney function among survivors at day 90 by indirectness (the recovery of kidney function in this high risk group is affected when the risk of death is taken into account). </p> <p>Data used to assess the impact of intensive versus less intensive CRRT on adverse events were obtained from three well‐conducted RCTs, providing treatment effects with clinically important harms; however, we downgraded the quality of evidence to moderate due to imprecision (CIs included both clinically important benefits and harm). One study provided data on hypophosphataemia. We rated this as high quality evidence. </p> </section> <section id="CD010613-sec-0080"> <h3 class="title" id="CD010613-sec-0080">Potential biases in the review process</h3> <p>While this review was conducted according to rigorous methods developed by the Cochrane Collaboration, some bias may be present in the review process. We searched for all relevant studies using sensitive and validated strategies in major medical databases and grey literature sources. However, it is possible that some studies (such as unpublished data and studies with negative or no effects) were not identified. An analysis for evidence to assess the risk of publication bias was not possible for all outcomes due to the small number of studies available in each meta‐analysis (<a href="#CD010613-fig-0004">Figure 4</a>). </p> <p>It was difficult to identify the number of patients who received IHD in the included study using a combination of both therapies (intermittent and continuous), as well also in studies evaluating CRRT intensity, in which patients remained dialysis‐dependent after ICU or hospital discharge, many were likely to have transitioned to IHD regardless of the original study‐assigned dose of CRRT. </p> <p>Several subgroup analyses were planned to explore potential sources of heterogeneity in our review, however a lack of data prevented us from doing these analyses. </p> </section> <section id="CD010613-sec-0081"> <h3 class="title" id="CD010613-sec-0081">Agreements and disagreements with other studies or reviews</h3> <p>Our systematic review in keeping with previous meta‐analysis on intensity in CRRT (<a href="./references#CD010613-bbs2-0055" title="NegashDT , DhingraVK , CoplandM , GriesdaleD , HendersonW . Intensity of continuous renal replacement therapy in acute kidney injury in the intensive care unit: a systematic review and meta‐analysis. Vascular &amp; Endovascular Surgery2011;45(6):504‐10. [MEDLINE: 21646231] ">Negash 2011</a>) or in mixed modality, combining intermittent, sustained and continuous dialysis (<a href="./references#CD010613-bbs2-0044" title="JunM , HiddoJ , HeerspinkL , NinomiyaT , GallagherM , BellomoR , et al. Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta‐analysis. Clinical Journal of The American Society of Nephrology: CJASN2010;5(6):956–63. [MEDLINE: 20395356] ">Jun 2010</a>; <a href="./references#CD010613-bbs2-0070" title="VanWertR , FriedrichJO , ScalesDC , WaldR , AdhikariNK , University of Toronto Acute Kidney Injury Research Group. High‐dose renal replacement therapy for acute kidney injury: systematic review and meta‐analysis. Critical Care Medicine2010;38(5):1360‐9. [MEDLINE: 20308884] ">Van Wert 2010</a>), has not found beneficial effects of more intensive RRT with respect to mortality and kidney recovery function in critically ill patients with AKI compared to less intensive therapy. </p> <p>There has been increased interest in recovery of kidney function. Indeed, lack of recovery of kidney function implies the need for long‐term dialysis associated with low quality of life. Our review has not demonstrated benefits on recovery of kidney function with intensive therapy. These findings are consistent with four individual RCTs (<a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a>; <a href="./references#CD010613-bbs2-0002" title="BoumanCS , Oudemans‐Van StraatenH , TijssenJG , ZandstraDF , KeseciogluJ . Effects of early high‐volume continuous venovenous haemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Critical Care Medicine2002;30(10):2205‐11. [MEDLINE: 12394945] ">Bouman 2002</a>; <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a>; <a href="./references#CD010613-bbs2-0006" title="LyndonW , WilleK , TolwaniA . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 177]. American Journal of Kidney Diseases2011;57(4):A61. [CENTRAL: 70379736] LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: comparing measured effluent volume to actual delivered dose [abstract no: 26]. 16th International Conference on CRRT; 2011 Feb 22‐25; San Diego, CA. 2011:127. LyndonWD , WilleKM , TolwaniAJ . Solute clearance in CRRT: prescribed dose versus actual delivered dose. Nephrology Dialysis Transplantation2012;27(3):952‐6. [MEDLINE: 21896498] TolwaniAJ , CampbellRC , StofanBS , LaiKR , OsterRA , WilleKM . Standard versus high‐dose CVVHDF for ICU‐related acute renal failure. Journal of the American Society of Nephrology2008;19(6):1233‐8. [MEDLINE: 18337480] TolwaniAJ , SpeerR , StofanB , LaiKR , WilleKM . A randomized prospective study comparing high dose continuous venovenous hemodiafiltration (CVVHDF) to standard CVVHDF in critically ill patients with acute renal injury [abstract no: 22]. Blood Purification2007;25:193. ">Tolwani 2008</a>) and do not agree with those reported of two previous RCTs (<a href="./references#CD010613-bbs2-0004" title="HoTB , JeffersonHJ , RhodesA . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441‐2. [MEDLINE: 11052612] RoncoC , BellomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet2000;356(9223):26‐30. [MEDLINE: 10892761] RoncoC , BelomoR , HomelP , BrendolanA , DanM , PiccinniP , et al. Effects of different doses in continuous veno‐venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Edtna‐Erca Journal2002;Suppl 2:7‐12. [MEDLINE: 12371727] RoncoC , HomelP , BellomoR , BrendolanA . Prospective randomised trial on dose delivery versus outcomes of RF treated by continuous veno‐venous hemofiltration (CVVH) [abstract no: A0717]. Journal of the American Society of Nephrology2000;11(Sept):133A. [CENTRAL: CN‐00644229] SchifflH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052611] ThanN , TurneyJH . Continuous haemofiltration in acute renal failure. Lancet2000;356(9239):1441. [MEDLINE: 11052610] ">Ronco 2000a</a>; <a href="./references#CD010613-bbs2-0005" title="SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. A prospective randomized trial comparing continuous hemodiafiltration versus hemofiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Journal of the American Society of Nephrology2004;15(Oct):763A. [CENTRAL: CN‐00724917] SaudanP , NiederbergerM , DeSeigneuxS , RomandJ , PuginJ , PernegerT , et al. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney International2006;70(7):1312‐7. [MEDLINE: 16850022] SaudanP , NiederbergerM , SellwegerM , PuginJ , RomandJ , PernegerT , et al. Continuous hemofiltration versus continuous hemodiafiltration in critically ill patients with acute renal failure [abstract no: PUB003]. Nephrology Dialysis Transplantation2003;18(Suppl 4):666. [CENTRAL: CN‐00447595] SaudanP , TriverioPA , RomandJA , PuginJ , MartinPY . Long‐term prognosis in critically ill patients with acute renal failure treated by continuous renal replacement therapy [abstract no: TH‐PO822]. Journal of the American Society of Nephrology2006;17(Abstracts):282A. [CENTRAL: CN‐00724918] TriverioPA , MartinPY , RomandJ , PuginJ , PernegerT , SaudanP . Long‐term prognosis after acute kidney injury requiring renal replacement therapy. Nephrology Dialysis Transplantation2009;24(7):2186‐9. [MEDLINE: 19228754] ">Saudan 2006</a>)<b>.</b> It is important to note that relevant differences on recovery of kidney function between <a href="./references#CD010613-bbs2-0001" title="AfshinniaF , BelangerK , PalevskyPM , YoungEW . Effect of ionized serum calcium on outcomes in acute kidney injury needing renal replacement therapy: secondary analysis of the acute renal failure trial network study. Renal Failure2013;35(10):1310‐8. [MEDLINE: 23992422] CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Dialysis catheter complications in the VA/NIH ATN study [abstract no: SA‐PO557]. Journal of the American Society of Nephrology2007;18(Abstracts):463A. CrowleyS , ScheinR , DevD , FinkelK , VijayanA , PaganiniE , et al. Lessons for successful study enrollment from the VA/NIH ATN study [abstract no: SA‐PO932]. Journal of the American Society of Nephrology2006;17(Abstracts):770A. [CENTRAL: CN‐00601950] CrowleyST , ChertowGM , VitaleJ , O'ConnorT , ZhangJ , ScheinRM , et al. Lessons for successful study enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2008;3(4):955‐61. [MEDLINE: 18385390] DemirjianS , PaganiniEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM . Severity of illness does not modify the effect of intensity of renal replacement therapy (RRT) on outcome in critically ill patients with AKI: results from the VA/NIH acute renal failure trial network (ATN) study [abstract no: SA‐PO2997]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):791A. DemirjianS , PagininiEP , ZhangJH , O'ConnorTZ , VitaleJ , PalevskyPM , et al. Predictive scoring systems perform poorly in critically ill patients with AKI requiring renal replacement: data from the VA/NIH Acute Renal Failure Trial Network (ATN) study [abstract no: SA‐PO3010]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):794A. JohansenKL , SmithMW , UnruhML , SirokaAM , O'ConnorTZ , PalevskyPM , et al. Predictors of health utility among 60‐day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. Clinical Journal of The American Society of Nephrology: CJASN2010 Aug;5(8):1366‐72. [MEDLINE: 20507953] JoyceVR , SmithMW , JohansenKL , UnruhML , SirokaAM , O'ConnorTZ , et al. Health‐related quality of life as a predictor of mortality among survivors of AKI. Clinical Journal of The American Society of Nephrology: CJASN2012;7(7):1063‐70. [MEDLINE: 22595826] PalevskyPM , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. Recovery of kidney function in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐PO2994]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):790A. PalevskyPM , O'ConnorT , ZhangJH , StarRA , SmithMW . Design of the VA/NIH Acute Renal Failure Trial Network (ATN) Study: intensive versus conventional renal support in acute renal failure. Clinical Trials2005;2(5):423‐35. [MEDLINE: 16317811] PalevskyPM , O'ConnorTZ , ChertowGM , CrowleyST , ZhangJH , KellumJA , et al. Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Critical Care (London, England)2010;13(4):310. [MEDLINE: 19678919] PalevskyPM , O'ConnorTZ , ZhangJH , StarR . VA/NIH Acute Renal Failure Trial: study design [abstract no: SA‐PO970]. Journal of the American Society of Nephrology2003;14(Program &amp; Abstracts):512A. [CENTRAL: CN‐00583741] PalevskyPM , OverbergerP , FranchiniR , O'ConnorTZ , ZhangJH , VA/NIH Acute Renal Failure Trial Network. One‐year outcomes in critically ill patients with acute kidney injury (AKI) treated with intensive versus less‐intensive renal replacement therapy (RRT) [abstract no: SA‐FC414]. Journal of the American Society of Nephrology2008;19(Abstracts Issue):93A. PalevskyPM , ZhangJ , O'ConnorT . Intensive versus non‐intensive renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) [abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto, Canada. 2008:A767. [CENTRAL: CN‐00716125] PesacretaM , OverbergerP , PalevskyPM , VA/NIH Acute Renal Failure Trial Network. Management of renal replacement therapy in acute renal failure: a survey of practitioner prescribing practices. [abstract no: SA‐PO227]. Journal of the American Society of Nephrology2004;15(Oct):350A. [CENTRAL: CN‐00601951] VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum appears in N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7‐20. [MEDLINE: 18492867] ZhangJH , O'ConnorT , PalevskyPM , for the VA/NIH Acute Renal Failure Trial Network Study. Evaluation of treatment separation in the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):523‐4. [CENTRAL: CN‐00783257] ZhangJH , O'ConnorT , SwansonK , PalevskyPM , VA/NIH Acute Renal Failure Trial Network Study. Evaluation of trial safety in an ICU trial: experience from the VA/NIH Acute Renal Failure Trial Network (ATN) Study [abstract]. Clinical Trials (London, England)2009;6(5):560. [CENTRAL: CN‐00783258] ZhangJH , PalevskyPM , ChertowGM , HartiganJ , O'ConnorTZ , GuarinoP , et al. Piecewise analysis of patient survival after onset of AKI. Clinical Journal of The American Society of Nephrology: CJASN2013;8(10):1679‐84. [MEDLINE: 23813558] ">ATN Study 2005</a> and <a href="./references#CD010613-bbs2-0003" title="BellomoR . Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney International2006;70(7):1202‐4. [MEDLINE: 16988729] BellomoR , CassA , ColeL , FinferS , GallagherM , KimI , et al. The relationship between hypophosphataemia and outcomes during low‐intensity and high‐intensity continuous renal replacement therapy. [Erratum appears in Crit Care Resusc. 2014 Jun;16(2):139 Note: McGuiness, Shay [corrected to McGuinness, Shay]]. Critical Care &amp; Resuscitation2014;16(1):34‐41. [MEDLINE: 24588434] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care (London, England)2014;18(2):R45. [MEDLINE: 24629036] BellomoR , CassA , ColeL , FinferS , GallagherM , LeeJ , et al. Daily protein intake and patient outcomes in severe acute kidney injury: findings of the randomized evaluation of normal versus augmented level of replacement therapy (RENAL) trial. Blood Purification2014;37(4):325‐34. [MEDLINE: 25171270] BellomoR , LipcseyM , CalzavaccaP , HaaseM , Haase‐FielitzA , LicariE , et al. Early acid‐base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine2013;39(3):429‐36. [MEDLINE: 23306586] FinferS , CassA , GallagherM , LeeJ , SuS , BellomoR , et al. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Critical Care &amp; Resuscitation2009;11(1):58‐66. [MEDLINE: 19281446] GallagherM , BellomoR , CassA , FinferS , GattasD , LeeJ , et al. Long term outcomes of severe AKI: results of the post‐RENAL study [abstract no: 071]. Nephrology2012;17(Suppl 2):45‐6. [EMBASE: 71377309] GallagherM , CassA , BellomoR , FinferS , GattasD , LeeJ , et al. Long‐term survival and dialysis dependency following acute kidney injury in intensive care: extended follow‐up of a randomized controlled trial. PLoS Medicine2014;11(2):e1001601. [MEDLINE: 24523666] JunM , BellomoR , CassA , GallagherM , LoS . Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal vs augmented level of replacement therapy trial [abstract no: 008]. Nephrology2012;17(Suppl 2):29‐30. [EMBASE: 71377246] RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Critical Care Medicine2012;40(6):1753‐60. [MEDLINE: 22610181] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal‐replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627‐38. [MEDLINE: 19846848] RENAL Replacement Therapy Trial Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Screening and study enrolment in the Randomized Evaluation of Normal vs. Augmented Level (RENAL) Replacement Therapy Trial. Blood Purification2009;27(2):199‐205. [MEDLINE: 19256108] RENAL Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Design and challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: high‐dose versus standard‐dose hemofiltration in acute renal failure. Blood Purification2008;26(5):407‐16. [MEDLINE: 18856012] RobertsD , RobertsM , LiuX , RobertsJ , LipmanJ , BellomoR . Clearance of antibiotics by high and low intensity continuous renal replacement therapy in critically ill patients [abstract no: 232]. Nephrology2010;15(Suppl 4):87. [EMBASE: 70467236] RobertsDM , LiuX , RobertsJA , NairP , ColeL , RobertsMS , et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care (London, England)2015;19(1):84. [MEDLINE: 25881576] WangAY , BellomoR , NinomiyaT , LoS , CassA , JardineM , et al. Angiotensin‐converting enzyme inhibitor usage and acute kidney injury: a secondary analysis of RENAL study outcomes. Nephrology2014;19(10):617‐22. [MEDLINE: 24894685] ">RENAL Study 2006</a> were observed (45.2% versus 13.3% of survivors depend on RRT at day 28 respectively). These differences may be due to several factors including different populations, prevalence of intermittent dialysis, pre‐existing chronic kidney disease and timing of RRT initiation. A review by <a href="./references#CD010613-bbs2-0058" title="PalevskyPM , BaldwinI , DavenportA , GoldsteinS , PaganiniE . Renal replacement therapy and the kidney: minimizing the impact of renal replacement therapy on recovery of acute renal failure. Current Opinion in Critical Care2005;11(6):548‐54. [MEDLINE: 16292058] ">Palevsky 2005</a> on factors affecting kidney recovery following AKI did not recommend either intensities with regard to recovery of kidney function when the mortality risk is taken into account (given that mortality is a competing end point for recovery of kidney function). </p> <p>The hypothesis that in critically ill patients, especially those with sepsis or systemic inflammatory responses, could benefit from an intensive CRRT was proposed by several researchers. It is interesting to note that we did not find benefit from higher intensity CRRT in this subgroup of patients in our review. These results were consistent with previous meta‐analysis (<a href="./references#CD010613-bbs2-0044" title="JunM , HiddoJ , HeerspinkL , NinomiyaT , GallagherM , BellomoR , et al. Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta‐analysis. Clinical Journal of The American Society of Nephrology: CJASN2010;5(6):956–63. [MEDLINE: 20395356] ">Jun 2010</a>; <a href="./references#CD010613-bbs2-0070" title="VanWertR , FriedrichJO , ScalesDC , WaldR , AdhikariNK , University of Toronto Acute Kidney Injury Research Group. High‐dose renal replacement therapy for acute kidney injury: systematic review and meta‐analysis. Critical Care Medicine2010;38(5):1360‐9. [MEDLINE: 20308884] ">Van Wert 2010</a>). Additionally, previous reviews explored the effect of high volume haemofiltration (HVHF) specifically in critically ill patients with severe sepsis or septic shock in an ICU setting (<a href="./references#CD010613-bbs2-0025" title="BorthwickEM , HillCJ , RabindranathKS , MaxwellAP , McAuleyDF , BlackwoodB . High‐volume haemofiltration for sepsis. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD008075.pub2] ">Borthwick 2013</a>; <a href="./references#CD010613-bbs2-0029" title="ClarkE , MolnarAO , Joannes‐BoyauO , HonoréPM , SikoraL , BagshawSM . High‐volume hemofiltration for septic acute kidney injury: a systematic review and meta‐analysis. Critical Care (London, England)2014;18(1):R7. [MEDLINE: 24398168] ">Clark 2014</a>; <a href="./references#CD010613-bbs2-0046" title="LehnerGF , WiedermannCJ , JoannidisM . High‐volume hemofiltration in critically ill patients: a systematic review and meta‐analysis. Minerva Anestesiologica2014;80(5):595‐609. [MEDLINE: 24292260] ">Lehner 2014</a>). These reviews applied different thresholds for HVHF: <a href="./references#CD010613-bbs2-0025" title="BorthwickEM , HillCJ , RabindranathKS , MaxwellAP , McAuleyDF , BlackwoodB . High‐volume haemofiltration for sepsis. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD008075.pub2] ">Borthwick 2013</a> defined HVHF as &gt; 35 mL/kg/h, while more recent reviews define HVHF as &gt;50 mL/kg/h (<a href="./references#CD010613-bbs2-0029" title="ClarkE , MolnarAO , Joannes‐BoyauO , HonoréPM , SikoraL , BagshawSM . High‐volume hemofiltration for septic acute kidney injury: a systematic review and meta‐analysis. Critical Care (London, England)2014;18(1):R7. [MEDLINE: 24398168] ">Clark 2014</a>) and HVHF and pulse high volume haemofiltration (PHVHF) as 85 mL/Kg/h (<a href="./references#CD010613-bbs2-0046" title="LehnerGF , WiedermannCJ , JoannidisM . High‐volume hemofiltration in critically ill patients: a systematic review and meta‐analysis. Minerva Anestesiologica2014;80(5):595‐609. [MEDLINE: 24292260] ">Lehner 2014</a>). These reviews included studies we excluded from our review due to the very‐high intensity applied (<a href="./references#CD010613-bbs2-0007" title="BoussekeyN , ChicheA , FaureK , DevosP , GueryB , d'EscrivanT , et al. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Medicine2008;34(9):1646‐53. [MEDLINE: 18542921] ">Boussekey 2008</a>; <a href="./references#CD010613-bbs2-0012" title="Joannes‐BoyauO , HonorePM , PerezP , BagshawSM , GrandH , CanivetJL , et al. High‐volume versus standard‐volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Medicine2013;39(9):1535‐46. [MEDLINE: 23740278] ">IVOIRE Study 2013</a>; <a href="./references#CD010613-bbs2-0017" title="SanchezC , CorbalanP , RodriguezF , SanchezA , PalominosS . Intensive high volume hemofiltration vs very high volume hemofiltration: effects on hemodynamics in patients with severe sepsis: a nursing approach [abstract no: 0432]. Intensive Care Medicine2010;36(2 Suppl 2):S193. ">Sanchez 2010b</a>; <a href="./references#CD010613-bbs2-0020" title="ZhangP , YangY , LvR , ZhangY , XieW , ChenJ . Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a single‐centre randomized clinical trial. Nephrology Dialysis Transplantation2012;27(3):967‐73. [MEDLINE: 21891773] ">Zhang 2012</a>) or no requirement of AKI for enrolment (<a href="./references#CD010613-bbs2-0013" title="JiangHL , XueWJ , LiDQ , YinAP , XinX , LiCH , et al. Influence of continuous veno‐venous hemofiltration on the course of acute pancreatitis. World Journal of Gastroenterology2005;11(31):4815‐21. [MEDLINE: 16097050] ">Jiang 2005</a>) These reviews found insufficient evidence of a therapeutic benefit for routine use of HVHF for septic AKI. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010613-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/urn:x-wiley:14651858:media:CD010613:CD010613-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_t/tCD010613-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD010613-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010613-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/urn:x-wiley:14651858:media:CD010613:CD010613-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_t/tCD010613-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010613-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010613-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/urn:x-wiley:14651858:media:CD010613:CD010613-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_t/tCD010613-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010613-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010613-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/urn:x-wiley:14651858:media:CD010613:CD010613-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_t/tCD010613-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 High Intensity versus less intensive CRRT, outcome: 1.1 Mortality" data-id="CD010613-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 High Intensity versus less intensive CRRT, outcome: 1.1 Mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010613-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/urn:x-wiley:14651858:media:CD010613:CD010613-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_t/tCD010613-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive versus less intensive CRRT, Outcome 1 Mortality." data-id="CD010613-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Intensive versus less intensive CRRT, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/references#CD010613-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010613-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/urn:x-wiley:14651858:media:CD010613:CD010613-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_t/tCD010613-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive versus less intensive CRRT, Outcome 2 Mortality in prespecified groups." data-id="CD010613-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Intensive versus less intensive CRRT, Outcome 2 Mortality in prespecified groups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/references#CD010613-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010613-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/urn:x-wiley:14651858:media:CD010613:CD010613-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_t/tCD010613-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive versus less intensive CRRT, Outcome 3 Recovery of kidney function." data-id="CD010613-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Intensive versus less intensive CRRT, Outcome 3 Recovery of kidney function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/references#CD010613-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010613-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/urn:x-wiley:14651858:media:CD010613:CD010613-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_t/tCD010613-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive versus less intensive CRRT, Outcome 4 Kidney function recovery in prespecified subgroup." data-id="CD010613-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Intensive versus less intensive CRRT, Outcome 4 Kidney function recovery in prespecified subgroup. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/references#CD010613-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010613-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/urn:x-wiley:14651858:media:CD010613:CD010613-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_t/tCD010613-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive versus less intensive CRRT, Outcome 5 Length of stay." data-id="CD010613-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Intensive versus less intensive CRRT, Outcome 5 Length of stay.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/references#CD010613-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010613-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/urn:x-wiley:14651858:media:CD010613:CD010613-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_t/tCD010613-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive versus less intensive CRRT, Outcome 6 Metabolic control." data-id="CD010613-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Intensive versus less intensive CRRT, Outcome 6 Metabolic control.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/references#CD010613-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010613-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/urn:x-wiley:14651858:media:CD010613:CD010613-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_t/tCD010613-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intensive versus less intensive CRRT, Outcome 7 Adverse events." data-id="CD010613-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Intensive versus less intensive CRRT, Outcome 7 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/references#CD010613-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/media/CDSR/CD010613/image_n/nCD010613-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010613-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intensive versus less intensive continuous renal replacement therapy (CRRT) for acute kidney injury (AKI)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intensive versus less intensive CRRT for AKI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with AKI<br/> <b>Settings:</b> ICU<br/> <b>Intervention:</b> Intensive versus less intensive CRRT </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Less intensive CRRT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Intensive CRRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality at day 30</b> <br/> Follow‐up: 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.88</b> <br/> (0.81 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2402 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>430 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>420 per 1000</b> <br/> (412 to 523) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality after 30 days post‐randomisation</b> <br/> Follow‐up: 60 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/> (0.80 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2759 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>514 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>483 per 1000</b> <br/> (416 to 565) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>593 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>557 per 1000</b> <br/> (480 to 652) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Patients free of RRT after discontinuing CRRT</b> <br/> Follow‐up: 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.12</b> <br/> (0.91 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2402 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>483 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>541 per 1000</b> <br/> (439 to 661) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>390 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>437 per 1000</b> <br/> (355 to 534) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Patients free of RRT after discontinuing CRRT</b> <br/> Follow‐up: 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/> (0.94 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>988 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>923 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>904 per 1000</b> <br/> (867 to 932) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>784 per 1000</b> <br/> (752 to 808) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events: hypophosphataemia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.21</b> <br/> (1.11 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1441 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>540 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>654 per 1000</b> <br/> (600 to 708) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>540 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>653 per 1000</b> <br/> (599 to 707) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval/s; <b>RR:</b> Risk ratio; <b>RRT</b>: renal replacement therapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ inconsistency: due to substantial heterogeneity (I<sup>2</sup> values ranged from 73% to 78%) </p> <p>² imprecision: due to wide CI which crossed the threshold for clinically meaningful effects </p> <p>³ Indirectness: critically ill patients with AKI in CRRT have high short‐term mortality risk; mortality is a competing end point for kidney recovery at day 90 </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intensive versus less intensive continuous renal replacement therapy (CRRT) for acute kidney injury (AKI)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010613-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intensive versus less intensive continuous renal replacement therapy (CRRT) for acute kidney injury (AKI): subgroups</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intensive versus less intensive CRRT for AKI: subgroups</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with AKI who need CRRT<br/> <b>Settings:</b> ICU<br/> <b>Intervention:</b> Intensive CRRT<br/> <b>Comparison:</b> Less intensive CRRT </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Standard dose</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> High dose </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality: patients with sepsis</b> <br/> Follow‐up: mean 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.94</b> <br/> (0.69 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>966 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>524 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>492 per 1000</b> <br/> (361 to 665) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>618 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>581 per 1000</b> <br/> (426 to 785) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality: patients without sepsis</b> <br/> Follow‐up: mean 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.89</b> <br/> (0.69 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1216 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>414 per 1000</b> <br/> (321 to 535) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>564 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>502 per 1000</b> <br/> (389 to 649) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality: patients with AKI related to cardiac or general surgery</b> <br/> Follow‐up: mean 21 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.73</b> <br/> (0.61 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>531 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>505 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>368 per 1000</b> <br/> (308 to 444) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>459 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>335 per 1000</b> <br/> (280 to 404) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality: patients with AKI not related to surgery</b> <br/> Follow‐up: mean 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.94</b> <br/> (0.73 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1871 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>414 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>389 per 1000</b> <br/> (302 to 497) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>550 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>517 per 1000</b> <br/> (402 to 660) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval/s; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ inconsistency: due to substantial heterogeneity (I<sup>2</sup> values ranged from 73% to 78%) </p> <p>² imprecision: due to wide CI which crossed the threshold for clinically meaningful effects </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intensive versus less intensive continuous renal replacement therapy (CRRT) for acute kidney injury (AKI): subgroups</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/full#CD010613-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010613-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intensive versus less intensive CRRT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Mortality at day 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.71, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Mortality after 30 days post‐randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.80, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality in prespecified groups <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Patients with sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.69, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Patients without sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.69, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Patients with SOFA cardiovascular score &lt; 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.71, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Patients with SOFA cardiovascular ≥ 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.92, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Patients with AKI related to surgical causes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.61, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Patients with AKI unrelated to surgical causes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.73, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Recovery of kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Free of RRT after discontinuing CRRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.91, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Free of RRT after discontinuing CRRT at day 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.96, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Free of RRT after discontinuing CRRT at day 90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.94, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Kidney function recovery in prespecified subgroup <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Patients with AKI related to surgical causes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.05, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Patients with AKI related to non‐surgical causes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.73, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Length of stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Days in hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐3.35, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Days in ICU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐3.73, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Metabolic control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Normalised metabolic acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Patients experiencing adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.73, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Hypophosphataemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.11, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Hypokalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.80, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.80, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.27, 2.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intensive versus less intensive CRRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010613.pub2/references#CD010613-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010613.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010613-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010613-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD010613-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010613\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010613\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010613\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010613\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010613\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010613.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010613.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010613.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010613.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010613.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718420672"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010613.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718420676"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010613.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dcfe67ec2935f',t:'MTc0MDcxODQyMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 